-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Shijiazhuang No.4 Pharmaceutical’s Rosuvastatin Calcium Tablets (5mg) Approved
Category:
Time：2022-06-15
Recently, the rosuvastatin calcium tablets (5mg) developed by Shijiazhuang No.4 Pharmaceutical Co., Ltd. have been granted a drug registration certificate by the National Medical Products Administration and are deemed to have passed the consistency evaluation.
Recently, the rosuvastatin calcium tablets (5mg) developed by Shijiazhuang No.4 Pharmaceutical Co., Ltd. have been granted a drug registration certificate by the National Medical Products Administration and are deemed to have passed the consistency evaluation. It is reported that rosuvastatin calcium tablets are primarily used for the treatment of primary hypercholesterolemia or mixed dyslipidemia.
Previously, Shijiazhuang No.4 Pharmaceutical’s rosuvastatin calcium tablets (10mg) received approval from the National Medical Products Administration in 2020 and passed the evaluation of bioequivalence and therapeutic equivalence for generic drugs. The recent approval of rosuvastatin calcium tablets (5mg) will further enhance the company’s product lineup.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license